ChatGPT analyzes speech patterns to identify Alzheimer’s 87 percent of the time, researchers show
By
Aaron Dorman
Feb 09, 2024
By reviewing speech patterns, ChatGPT was able to correctly identify Alzheimer’s 87% of the time, a new study shows.
Financial burden of dementia poses challenges for older adults, caregivers, payers: researchers
By
Kimberly Bonvissuto
Feb 09, 2024
The growing population of older adults brings with it an increased prevalence of Alzheimer’s disease and related dementias. Two new papers look at the increasing financial burden on people living with...
New fluorescence imaging technique makes toxic Alzheimer’s proteins ‘glow’ for earlier-than-ever...
By
Aaron Dorman
Feb 08, 2024
An innovative sensor was able to detect toxic beta amyloid proteins, which cause Alzheimer’s, with a new fluorescence “fingerprint” technique.
Lower Alzheimer’s risk seen with PDE5i initiation for erectile dysfunction
Feb 08, 2024
The greatest reduction in risk was seen for those receiving 21 to 50 phosphodiesterase type 5 inhibitor prescriptions.
Alzheimer’s prediction tool pinpoints where seniors fall along the timeline dementia
By
Aaron Dorman
Feb 05, 2024
A new online tool offers a prediction of how people with early-stage dementia are expected to develop worsening conditions such as Alzheimer’s.
More news for Monday, Feb. 5
By
Kimberly Bonvissuto
Feb 05, 2024
Takeaways from NIC MAP’s fourth-quarter fundamentals release … Use of Medicaid wraparound services by dually eligible individuals varies by service, state … StartUp Health launches global Alzheimer’s...
Holistic dementia care reduces staff burdens, enhances provider market position
By
Paul Tanico
Feb 01, 2024
By adopting a comprehensive strategy that balances clinical insights, lifestyle interventions and economic considerations, staff members can unlock the potential for improved outcomes and elevate the facility’s...
Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
Strategies needed to improve delivery of Alzheimer’s disease-modifying therapies
Jan 30, 2024
Models that enable primary care practitioners to diagnose disease and evaluate patients for treatment eligibility would have biggest effect on wait times, the study found.
Visionary Alzheimer’s forecasting software gets FDA approval
By
Aaron Dorman
Jan 30, 2024
A newly regulated Alzheimer’s software tool offers clarity on whether the condition is likely to progress to dementia in someone with mild cognitive impairment.